Contact this trialFirst, we need to learn more about you.
KRAS G12C inhibitor
JAB-21822 + Cetuximab for Solid Tumors
Recruiting2 awardsPhase 1 & 2
Jacksonville, Florida
This trial is to study the safety of JAB-21822 as a single treatment and in combination with other treatments for adults with solid tumors that have a KRAS G12C mutation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.